Drugs / Recombinant Human GCSF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00776165 | Oct 2007 → Jul 2009 | neutropenia | Shantha Biotechnics Limited | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human GCSF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00776165 ↗ |
| Known as | rhG-CSF | “Group 1: Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF)(Shantha)” NCT00776165 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Granulocyte Colony Stimulating Factor” NCT00776165 ↗ |
| Route | Intravenous | “administered subcutaneous/intravenous/continuous subcutaneous infusion” NCT00776165 ↗ |
| Route | Subcutaneous | “administered subcutaneous/intravenous/continuous subcutaneous infusion” NCT00776165 ↗ |